In the non-randomized phase 3b/4 DESTINY-Breast12 study, trastuzumab deruxtecan (T-DXd) treatment of patients with HER2+ advanced breast cancer and active or stable brain metastases showed consistent intracranial activity and systemic efficacy of T-DXd. This evidence concerns the gene ERBB2 and breast carcinoma.